Results 251 to 260 of about 139,370 (300)
Some of the next articles are maybe not open access.
American Heart Journal, 2010
Antiplatelet therapy is a cornerstone of the management of patients with acute coronary syndromes or for those undergoing percutaneous coronary intervention. As the intricacies of platelet biology and mechanisms of thrombus formation are revealed, novel antiplatelet therapies have emerged.
Michael A, Gaglia +2 more
openaire +2 more sources
Antiplatelet therapy is a cornerstone of the management of patients with acute coronary syndromes or for those undergoing percutaneous coronary intervention. As the intricacies of platelet biology and mechanisms of thrombus formation are revealed, novel antiplatelet therapies have emerged.
Michael A, Gaglia +2 more
openaire +2 more sources
Clinics in Haematology, 1981
Much new information has been gleaned about the morphology, biochemistry and function of platelets. The pathophysiology of atherosclerosis and thromboembolic disorders appears to be related to abnormal platelet function. Endothelial damage, thromboxane A2, Thrombin, adenosine diphospate and epinephrine may each promote platelet aggregation, whereas ...
openaire +4 more sources
Much new information has been gleaned about the morphology, biochemistry and function of platelets. The pathophysiology of atherosclerosis and thromboembolic disorders appears to be related to abnormal platelet function. Endothelial damage, thromboxane A2, Thrombin, adenosine diphospate and epinephrine may each promote platelet aggregation, whereas ...
openaire +4 more sources
Antiplatelet therapy – ticagrelor
Hämostaseologie, 2012SummaryTicagrelor, a cyclopentyltriazolopyrimidine (CPTP), is the representative of a new chemical class of P2Y12 receptor inhibitors that differ from thienopyridines (ticlopidin, clopidogrel, prasugrel) as ticagrelor is not a prodrug requiring active biotransformation by cytochromes in the liver and thus is characterized by a more rapid, more ...
E, Giannitsis, H A, Katus
openaire +2 more sources
Monitoring Antiplatelet Therapy
Seminars in Thrombosis and Hemostasis, 2017The increasing use of antiplatelet therapy, particularly aspirin and oral P2Y12 inhibitors, in the prevention and management of arterial thrombosis, has stimulated extensive pharmacodynamic studies and research into tailored antiplatelet regimens. Many different methodologies have been studied for monitoring antiplatelet drugs and some are now well ...
Rachel, Orme +2 more
openaire +2 more sources
Current Atherosclerosis Reports, 2011
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources
The American Journal of Medicine, 1996
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
Hospital Medicine, 2000
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Perioperative antiplatelet therapy.
American family physician, 2010Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular dis- ease. Clopidogrel therapy is mandatory for six weeks after placement of bare-metal stents, three to six months after myocardial infarction, and at least 12 months after placement of drug-eluting stents.
Chassot, P G +3 more
openaire +2 more sources